S&P/ASX 200 Index (ASX: XJO) shares are up 0.03% at 9,095.2 points on the final day of reporting season.

Hundreds of companies have revealed their earnings this season.

Brokers have reviewed the reports and updated their ratings and 12-month price targets accordingly.

Here are five buy-rated ASX 200 shares with significant upside potential ahead, according to the experts.

NextDC Ltd (ASX: NXT)

The NextDC share price is $13.63, down 1.7% today and down 17% over 12 months.

UBS renewed its buy rating on NextDC shares, with a $22.55 target after reviewing the company’s FY26 earnings.

This implies potential capital growth of 61% over the next year.

WiseTech Global Ltd (ASX: WTC)

The WiseTech share price is $41.39, up 1.9% today and down 58% over 12 months.

Morgans reiterated its buy rating on this ASX 200 tech share after the company’s FY26 results.

The broker reduced its 12-month price target from $67 to $62.50.

However, this still implies a healthy potential upside of 52%.

Droneshield Ltd (ASX: DRO)

The Droneshield share price is $1.74, down 0.7% today and down 46% over 12 months.

Bell Potter renewed its buy rating on this ASX 200 industrials share after its 1H FY26 results.

The broker trimmed its 12-month price target from $2.50 to $2.40.

This suggests a potential 35% upside ahead.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is $9.56, down 0.3% today and down 17% over 12 months. 

Morgan Stanley kept its buy call in place on Qantas shares following the airline’s FY26 results.

The broker raised its target on the ASX 200 industrials share from $12.50 to $12.80.

This suggests a potential 33% upside ahead.

Objective Corporation Ltd (ASX: OCL)

The Objective Corporation share price is $6.40, down 5.9% today and down 69% over 12 months. 

Morgans maintained its buy recommendation on this ASX 200 tech share after the company’s FY26 results.

The broker has a revised 12-month price target of $8.50, implying a potential 33% upside ahead.

OCL’s FY26 result was largely in line with expectations. The result came however with more sticker shock in the form of another legacy contract loss leading to a further $3.2m ARR reduction.

OCL enters FY27 with ARR of $114.1m. Despite this softening & FX headwinds during the year, OCL continued to see strong underlying SaaS growth momentum and progress of a number of strategic milestones (including the launch of Build Australia), which is key to ARR momentum and FY27+ outlook.

Rebasing our forecasts for OCL’s revised FY27 ARR and guidance sees our NPAT estimates reduce by ~18-21% in FY27-28F.

Following these revisions OCL is trading on FY27F P/E of 24x, with a share price near 5 years lows.

The post 5 ASX 200 shares with 33% to 61% upside post-results: experts appeared first on The Motley Fool Australia.

More reading

• Morgans names 3 ASX tech stocks to buy
• Why I think Xero and WiseTech shares are strong buys
• These are the 10 most shorted ASX shares
• 4 ASX shares I’d buy with $5,000 in September
• 3 ASX growth shares to buy in September

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield, Objective, and WiseTech Global. The Motley Fool Australia has positions in and has recommended Objective and WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX healthcare share Sonic Healthcare Ltd (ASX: SHL) could be one of the best picks within the S&P/ASX 200 Index (ASX: XJO) for retirees wanting dividends.

Sonic Healthcare describes itself as one of the world’s leading medical diagnostic companies. It operates in nine countries, including Australia, the UK, Germany, the US, and Switzerland, with 330 laboratories and 47,000 employees. Impressively, it’s the number one player in six countries.

For multiple reasons, I think it’s a great option for retirees.

Defensive earnings

Healthcare is a defensive sector because of the nature of the types of services it provides.

People don’t choose when to become sick or injured – healthcare demand doesn’t change like discretionary spending does. I’d imagine most people (and governments) would prioritise spending on health over most other categories.

Sonic Healthcare provides an essential service in the healthcare process, so I think its earnings are very defensive.

The ASX healthcare share reported an impressive set of numbers in FY26, considering the economic uncertainty.

Revenue grew 13% to $10.9 billion, underlying operating earnings (EBITDA) climbed 11% to $1.9 billion, and underlying earnings per share (EPS) grew 14% to $1.256.

Profit growth is key for a business to deliver a stable and rising dividend because profit pays for passive income. Therefore, even retiree passive income investors need to look at the earnings outlook.

Good dividend credentials

The ASX healthcare share has paid dividends since 1994. It has increased its dividend almost every year since 1994, except in 2011 and 2012, when it maintained it.

There are very few ASX businesses out there that have increased their payout as consistently over the last 25 years.

I expect the business will be able to continue growing its payout for the foreseeable future.

In the 2026 financial year, Sonic Healthcare continued its progressive dividend policy, hiking the payout by 1 cent per share to $1.08. That translates into a dividend yield of 5.4% excluding franking credits and around 7% including franking credits.  

That’s a really attractive starting yield for retirees, in my opinion.

The ASX healthcare share has earnings tailwinds

I expect the business will be able to increase its payout in the coming years because its earnings could grow materially.

Demand for its services could grow for the foreseeable future, driven by the ageing and growing population in the company’s core markets.

Another way that the company can grow its earnings is by making the occasional acquisition. Its focus in recent times has been Europe. This tactic gives the business a much stronger scale in that market, boosting profit margins.

Over time, I think this business can continue to grow its profits and dividends, making it a compelling pick for investors.

The post Why this ASX healthcare share is a retiree’s dream for FY27 appeared first on The Motley Fool Australia.

More reading

• Why I think these boring ASX shares could build serious wealth
• 37 ASX shares going ex-dividend next week
• How much superannuation is needed to target a $50,000 annual passive income?
• 3 top Australian shares to buy for passive income
• Buy, hold, sell: Super Retail, APA, Sonic Healthcare shares

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares are marching higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech giant closed on Friday trading for $172.32. In late morning trade on Monday, shares are changing hands for $173.38 apiece, up 0.6%.

For some context, the ASX 200 is up 0.3% at this same time.

Today’s outperformance is par for the course for stockholders since CSL shares closed at a multi-year low of $92.24 on 3 June.

Indeed, with today’s intraday moves factored in, the share price is up a whopping 88.0% since plumbing that low water mark less than three months ago.

Atop those capital gains, investors who hold the stock at market close next Tuesday, 8 September, will receive the final unfranked CSL dividend of $2.277 a share. CSL will pay that dividend on 2 October.

CSL stock trades on a 2.4% unfranked dividend yield (partly trailing partly pending).

Why did the ASX 200 biotech stock plunge to multi-year lows in June?

Despite the remarkable turnaround since 3 June, CSL shares remain down 39% since January 2025.

The company has faced a number of headwinds that saw investors reaching for their sell buttons.

Among these, was the management’s announcement of their intent to spin off the CSL Seqirus segment, its influenza vaccine business, into a separate ASX-listed company.

The company has also been hit by lower than forecast plasma demand, which were partly to blame for CSL’s repeated earnings downgrades.

And investors were taken off guard by former CSL CEO Paul McKenzie’s unexpected exit in February this year.

But, judging by the surging share price these last three months, CSL’s FY 2026 ‘reset’ looks to be paying off handsomely.

And looking to ahead, Morgans’ Damien Nguyen believes the ASX 200 biotech stock remains an appealing opportunity (courtesy of The Bull).

Here’s why.

Should I buy CSL shares today?

“CSL is a global healthcare leader with strong competitive advantages across plasma therapies, vaccines and specialty medicines,” Nguyen said. “Demand for its products remain largely independent of economic conditions.”

Summarising his buy recommendation on CSL shares, Nguyen concluded:

In our view, the latest full year result in 2026 is generating confidence that repeated earnings downgrades are behind CSL.

With defensive earnings, global market leadership and attractive long term growth prospects, we view CSL as an appealing investment opportunity.

What did CSL report for FY 2026?

CSL announced its FY 2026 results on 18 August.

While the company reported a 1% year-on-year decline in revenue to US$15.8 billion, that came in well ahead of its revised guidance (issued in May) of US$15.2 billion.

Management also painted a more positive outlook for FY 2027.

“FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth,” CSL interim CEO Gordon Naylor said.

CSL expects steady revenue in FY 2027, while underlying net profit after tax (NPAT) is forecast to grow by around 5%.

CSL shares closed up 17.3% on the day the results were released.

The post Up 88%! Why CSL shares remain an ‘appealing’ buy today appeared first on The Motley Fool Australia.

More reading

• Experts name 2 ASX 200 blue chip shares to buy this week
• Buy, hold, sell: Commonwealth Bank, Goodman Group, CSL shares
• CSL shares have surged 49%: Are brokers finally turning bullish?
• Should I buy CSL shares before the end of August?
• Buy, hold, sell: CSL, BHP, Westpac shares

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.